

Supplemental Information for:

**Penta-ALFA-tagged substrates for self-labelling tags allow signal enhancement in microscopy**

Souvik Ghosh<sup>1</sup>, Ramona Birke<sup>1</sup>, Ashwin Karthick Natarajan<sup>2</sup>, Johannes Broichhagen<sup>1,\*</sup>

---

<sup>1</sup> *Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Robert-Rössle-Str. 10, 13125 Berlin, Germany.*

<sup>2</sup> *Max-Delbrück-Centrum für Molekulare Medizin (MDC), Robert-Rössle-Str. 10, 13092 Berlin, Germany*

To whom correspondence should be addressed:

broichhagen@fmp-berlin.de

## Table of Contents

<b>1. General</b>	<b>3</b>
<b>2. Synthesis</b>	<b>4</b>
2.1. General Procedure for SPPS	4
2.2. <i>N</i> <sub>3</sub> -ALFA <sub>5</sub>	5
2.3. 2-((1 <i>E</i> ,3 <i>E</i> )-5-(( <i>E</i> )-1-(6-((2-(2-((6-Chlorohexyl)oxy)ethoxy)ethyl)amino)-6-oxohexyl)-3,3-dimethylindolin-2-ylidene)penta-1,3-dien-1-yl)-1-(6-((2,5-dioxopyrrolidin-1-yl)oxy)-6-oxohexyl)-3,3-dimethyl-3 <i>H</i> -indol-1-ium trifluoro acetate (2)	6
2.4. 2-((1 <i>E</i> ,3 <i>E</i> )-5-(( <i>E</i> )-1-(6-((4-(((2-Amino-9 <i>H</i> -purin-6-yl)oxy)methyl)benzyl)amino)-6-oxohexyl)-3,3-dimethylindolin-2-ylidene)penta-1,3-dien-1-yl)-1-(6-((2,5-dioxopyrrolidin-1-yl)oxy)-6-oxohexyl)-3,3-dimethyl-3 <i>H</i> -indol-1-ium trifluoro acetate (3)	7
2.5. 1-(6-((2-(3-((2-Aminoethyl)amino)-3-oxopropoxy)ethyl)amino)-6-oxohexyl)-2-((1 <i>E</i> ,3 <i>E</i> )-5-(( <i>E</i> )-1-(6-((2-(2-((6-chlorohexyl)oxy)ethoxy)ethyl)amino)-6-oxohexyl)-3,3-dimethylindolin-2-ylidene)penta-1,3-dien-1-yl)-3,3-dimethyl-3 <i>H</i> -indol-1-ium trifluoroacetate (4)	bis 8
2.6. 1-(1-Amino-4,35-dioxo-7,10,13,16,19,22,25,28,31-nonaoxa-3,34-diazatetracontan-40-yl)-2-((1 <i>E</i> ,3 <i>E</i> )-5-(( <i>E</i> )-1-(6-((4-(((2-amino-9 <i>H</i> -purin-6-yl)oxy)methyl)benzyl)amino)-6-oxohexyl)-3,3-dimethylindolin-2-ylidene)penta-1,3-dien-1-yl)-3,3-dimethyl-3 <i>H</i> -indol-1-ium trifluoro acetate (5)	bis 9
2.7. ALFA <sub>5</sub> -Cy5-HTL	10
2.8. ALFA <sub>5</sub> -Cy5-BG	11
<b>3. Protein expression and purification</b>	<b>12</b>
<b>4. Protein mass spectroscopy</b>	<b>13</b>
<b>5. Supplementary Figure</b>	<b>14</b>
<b>6. Cell culture and imaging</b>	<b>14</b>
<b>7. Non-denaturing SDS-PAGE</b>	<b>15</b>
<b>8. Image Calculation and Statistics</b>	<b>15</b>
<b>9. Excitation and Emission profiles</b>	<b>16</b>
<b>10. References</b>	<b>16</b>

## 1. General

All chemical reagents and anhydrous solvents for synthesis were purchased from commercial suppliers (Sigma-Aldrich, Acros, TCI, IRIS–Biotech, Novabiochem–Merck) and were used without further purification if not stated otherwise. Nb643 was purchased from nano-tag (FluoTag®-X2 anti-ALFA; Cat No: N1502-At643-L), and is reported to carry 2 fluorophores per nanobody (<https://nano-tag.com/product/fluotag-x2-anti-alfa/>).

NMR spectra were recorded at 300 K in deuterated solvents on a Bruker AVANCE III HD 600 equipped with a CryoProbe or on Bruker AV-III spectrometers using either a cryogenically cooled 5 mm TCI-triple resonance probe equipped with one-axis self-shielded gradients or room temperature 5 mm broadband probe and calibrated to residual solvent peaks ( $^1\text{H}/^{13}\text{C}$  in ppm): MeOD- $d_4$  (3.31/49.00). Multiplicities are abbreviated as follows: s = singlet, d = doublet, t = triplet, q = quartet, p = pentet, h = heptet, br = broad, m = multiplet. Coupling constants  $J$  are reported in Hz. Spectra are reported based on appearance, not on theoretical multiplicities derived from structural information.

LC-MS was performed on an Agilent 1260 Infinity II LC System equipped with Agilent SB-C18 column (1.8  $\mu\text{m}$ ,  $2.1 \times 50$  mm). Buffer A: 0.1% FA in  $\text{H}_2\text{O}$  Buffer B: 0.1% FA acetonitrile. The typical gradient was from 10% B for 0.5 min  $\rightarrow$  gradient to 95% B over 5 min  $\rightarrow$  95% B for 0.5 min  $\rightarrow$  gradient to 99% B over 1 min with 0.6 mL/min flow. Retention times ( $t_R$ ) are given in minutes (min). Chromatograms were imported into Graphpad Prism8 and purity was determined by calculating AUC ratios.

Preparative or semi-preparative HPLC was performed on an Agilent 1260 Infinity II LC System equipped with columns as followed: preparative column –Reprospher 100 C18 columns (10  $\mu\text{m}$ : 50 x 30 mm at 20 mL/min flow rate; semi-preparative column – 5  $\mu\text{m}$ : 250 x 10 mm at 4 mL/min flow rate. Eluents A (0.1% TFA in  $\text{H}_2\text{O}$ ) and B (0.1% TFA in MeCN) were applied as a linear gradient. Peak detection was performed at maximal absorbance wavelength.


High resolution mass spectrometry was performed on an Agilent Technologies 6230 series accurate mass TOF LC-MS linked to an Agilent Technologies 1290 Infinity Series machine with a Thermo Accucore™ RP-MS column, 2.6  $\mu\text{m}$  pore size,  $30 \times 2.1$  mm, and a 3 min gradient from 5 to 99% aqueous MeCN with 0.1% TFA and MeCN with 0.1% TFA. flow rate: 0.8 mL/min; UV-detection: 220 nm, 254 nm, 300 nm.

## 2. Synthesis

### 2.1. General Procedure for SPPS


Peptides were prepared by SPPS on a 50  $\mu$ M scale using a peptide synthesizer (Automated microwave peptide synthesizer, CEM) and a standard Fmoc/t-Bu protocol. The synthesis was performed on a TentaGel S Ram resin (RappPolymere, Tübingen, Germany). Couplings were achieved by reacting 0.2 M Fmoc-AA-OH with 0.25 M DIC and 0.25 M Oxyma in DMF. A solution of 20% Piperidine in DMF was used to remove the Fmoc protection group. The acetylation is carried out with 3.5 ml DMF, 1 mL acetic anhydride and 0.5 ml DIPA overnight at room temperature. Peptides were deprotected and cleaved from the resin using a mixture of 10 mL TFA, 0.75 g phenol, 0.5 mL water, 0.5 mL methylphenylsulfide, and 0.25 mL 1,2-ethanedithiol. After 3 h at room temperature, the cleavage solution was collected, and the crude peptides were precipitated from ice-cold *tert*-butyl-methyl ether. Crude peptides were washed five times with dry diethyl ether. Final RP-HPLC purification and analysis were achieved using a linear solvent gradient (eluent A: 0.05% TFA in water; eluent B: 0.05% TFA in acetonitrile; linear gradient from 5 to 60% B over 30 min at a flow rate of 20 ml·min<sup>-1</sup>, RT) over a Vydac C18 column (Hesperia, CA, US) and detection takes place at 220 nm.

## 2.2. N<sub>3</sub>-ALFA<sub>5</sub>



Ac-AzidoLys-(PEG<sub>2</sub>-ALFA)<sub>5</sub>-G-NH<sub>2</sub> = N<sub>3</sub>-ALFA<sub>5</sub> by SPPS

### <Chromatogram>




### <Peak Table>

Peak#	Ret. Time	Area	Height	Conc.	Unit	Mark	Name
1	13.133	13467572	128508	0.000			
Total		13467572	128508				

LRMS (ESI): calc. for C<sub>435</sub>H<sub>761</sub>N<sub>146</sub>O<sub>143</sub> [M+13H]<sup>13+</sup>: 794.0, found: 794.2; calc. for C<sub>435</sub>H<sub>762</sub>N<sub>146</sub>O<sub>143</sub> [M+14H]<sup>14+</sup>: 737.3, found: 737.2; calc. for C<sub>435</sub>H<sub>763</sub>N<sub>146</sub>O<sub>143</sub> [M+15H]<sup>15+</sup>: 688.2, found: 688.5.


**2.3. 2-((1*E*,3*E*)-5-((*E*)-1-(6-((2-(2-((6-Chlorohexyl)oxy)ethoxy)ethyl)amino)-6-oxohexyl)-3,3-dimethylindolin-2-ylidene)penta-1,3-dien-1-yl)-1-(6-((2,5-dioxopyrrolidin-1-yl)oxy)-6-oxohexyl)-3,3-dimethyl-3*H*-indol-1-ium trifluoro acetate (2)**




TSTU (45.4 mg, 151  $\mu\text{mol}$ , 2.2 equiv.) and DIPEA (35.8  $\mu\text{L}$ , 205.8  $\mu\text{mol}$ , 3.0 equiv.) were added to compound Cy5-bis acid (40.0 mg, 68.6  $\mu\text{mol}$ , 1.0 equiv.) in DMSO (2 mL) and stirred it for 30 mins before HTL-NH<sub>2</sub> (10.6  $\mu\text{L}$ , 48.2  $\mu\text{mol}$ , 0.70 equiv.) was added. The reaction mixture was stirred for another 1 h before quenched with 2 mL of water, 40  $\mu\text{L}$  of acetic acid and subjected to RP-HPLC purification. The product containing fractions were pooled and the desired product was obtained after lyophilization (17 mg, 17.0  $\mu\text{mol}$ , 25%) as a blue powder.

**HRMS (ESI):** calc. for C<sub>51</sub>H<sub>71</sub>ClN<sub>4</sub>O<sub>7</sub> [M]<sup>+</sup>: 886.5000, found: 886.5030.

**LCMS traces:**



**2.4. 2-((1*E*,3*E*)-5-((*E*)-1-(6-((4-(((2-Amino-9*H*-purin-6-yl)oxy)methyl)benzyl)amino)-6-oxohexyl)-3,3-dimethylindolin-2-ylidene)penta-1,3-dien-1-yl)-1-(6-((2,5-dioxopyrrolidin-1-yl)oxy)-6-oxohexyl)-3,3-dimethyl-3*H*-indol-1-ium trifluoroacetate (3)**




TSTU (22.7 mg, 75.5  $\mu\text{mol}$ , 2.2 equiv.) and DIPEA (17.9  $\mu\text{L}$ , 103  $\mu\text{mol}$ , 3 equiv.) were added to the compound Cy5-bis acid (20.0 mg, 34.3  $\mu\text{mol}$ , 1 equiv.) in DMSO (2 mL) and stirred it for 30 mins before BG-NH<sub>2</sub> (5.56 mg, 20.6  $\mu\text{mol}$ , 0.6 equiv.) was added. The reaction mixture was stirred for another 1 h before quenched with 2 mL of water, 40  $\mu\text{L}$  of acetic acid and subjected to RP-HPLC purification. The product containing fractions were


pooled and the desired product was obtained after lyophilization (8.6 mg, 8.2  $\mu\text{mol}$ , 24%) as a blue powder.

**LRMS (ESI):** calc. for C<sub>54</sub>H<sub>63</sub>N<sub>9</sub>O<sub>6</sub> [M+H]<sup>2+</sup>: 466.7445, found: 466.7471.

**LCMS traces:**



**2.5. 1-(6-((2-(3-((2-Aminoethyl)amino)-3-oxopropoxy)ethyl)amino)-6-oxohexyl)-2-((1*E*,3*E*)-5-((*E*)-1-(6-((2-(2-((6-chlorohexyl)oxy)ethoxy)ethyl)amino)-6-oxohexyl)-3,3-dimethylindolin-2-ylidene)penta-1,3-dien-1-yl)-3,3-dimethyl-3*H*-indol-1-ium bis trifluoroacetate (4)**




Compound **2** (15.0 mg, 16.9  $\mu\text{mol}$ , 1 equiv.), Fmoc-PEG<sub>9</sub>-COOH (23.9 mg, 33.8  $\mu\text{mol}$ , 2 equiv.) and DIPEA (17.7  $\mu\text{L}$ , 101  $\mu\text{mol}$ , 6 equiv.) were dissolved in acetonitrile (2 mL) and stirred at 80 °C for 2 h. The reaction mixture was cooled down to room temperature. Then, TSTU (10.2 mg, 16.9  $\mu\text{mol}$ , 2 equiv.) was added to the reaction mixture and stirred at 20 °C for 30 min before ethylene diamine (1.13  $\mu\text{L}$ , 16.9  $\mu\text{mol}$ , 1 equiv.) was added. The reaction mixture was


stirred further for another 1 h before quenched with 2 mL of water, 40  $\mu\text{L}$  of acetic acid and subjected to RP-HPLC purification. The product containing fractions were pooled and the desired product was obtained after lyophilization (7.6 mg, 4.97  $\mu\text{mol}$ , 29%) as a blue powder.

**HRMS** (ESI): calc. for C<sub>70</sub>H<sub>115</sub>ClN<sub>6</sub>O<sub>14</sub> [M+H]<sup>2+</sup>: 649.4075, found: 649.4038.

**LCMS traces:**



**2.6. 1-(1-Amino-4,35-dioxo-7,10,13,16,19,22,25,28,31-nonaoxa-3,34-diazatetracontan-40-yl)-2-((1*E*,3*E*)-5-((*E*)-1-(6-(((2-amino-9*H*-purin-6-yl)oxy)methyl)benzyl)amino)-6-oxohexyl)-3,3-dimethylindolin-2-ylidene)penta-1,3-dien-1-yl)-3,3-dimethyl-3*H*-indol-1-ium bis trifluoro acetate (5)**




Compound **3** (7.0 mg, 7.50  $\mu\text{mol}$ , 1 equiv.), Fmoc-PEG<sub>9</sub>-COOH (10.6 mg, 15.0  $\mu\text{mol}$ , 2 equiv.) and DIPEA (7.84  $\mu\text{L}$ , 45.0  $\mu\text{mol}$ , 6 equiv.) were dissolved in acetonitrile (1 mL) and stirred at 80 °C for 2 h. The reaction mixture was cooled down to room temperature. Then, TSTU (4.52 mg, 15.0  $\mu\text{mol}$ , 2 equiv.) was added to the reaction mixture and stirred at 20 °C for 30 min before ethyl diamine (0.50  $\mu\text{L}$ , 7.50  $\mu\text{mol}$ , 1 equiv.) (from stock


solution of 2  $\mu\text{L}$  in 10  $\mu\text{L}$  of DMSO) was added. The reaction mixture was stirred further for another 1 h before quenched with 1 mL of water, 20  $\mu\text{L}$  of acetic acid and subjected to RP-HPLC purification. The product containing fractions were pooled and the desired product was obtained after lyophilization (2.80 mg, 1.8  $\mu\text{mol}$ , 24%) as a blue powder.

**HRMS** (ESI): calc. for C<sub>73</sub>H<sub>108</sub>N<sub>11</sub>O<sub>13</sub> [M+2H]<sup>3+</sup>: 448.9371, found: 448.9323.

**LCMS traces:**




## 2.7. ALFA<sub>5</sub>-Cy5-HTL




DBCO-NHS ester (0.66 mg, 1.54  $\mu\text{mol}$ , 1 equiv.) in DMSO (10  $\mu\text{L}$ ) (from the fresh stock solution of 1.32 mg in 20  $\mu\text{L}$  of DMSO) was added to compound **4** (2.0 mg, 1.54  $\mu\text{mol}$ , 1 equiv.), DIPEA (1.07  $\mu\text{L}$ , 6.16  $\mu\text{mol}$ , 4 equiv.) in DMSO (50  $\mu\text{L}$ ) and stirred at 20  $^{\circ}\text{C}$  for 30 min. Then, 15  $\mu\text{L}$  of reaction mixture was taken off and added to the N<sub>3</sub>-(PEG<sub>2</sub>-ALFA)<sub>5</sub> (7.78 mg, 0.58  $\mu\text{mol}$ , 1.5 equiv.) in distilled H<sub>2</sub>O (50  $\mu\text{L}$ ). The reaction mixture was stirred further for 6 h before 65  $\mu\text{L}$  of acetonitrile, 1  $\mu\text{L}$  of acetic acid were added and subjected to RP-HPLC purification. The product containing fractions were pooled and the desired product was obtained after lyophilization (1.98 mg, 165 nmol, 19%) as a blue powder.

**HRMS** (ESI): calc. for C<sub>526</sub>H<sub>879</sub>CIN<sub>153</sub>O<sub>159</sub> [M]<sup>+</sup>: 11926.2, found: 11924.8.

**LCMS traces:**




## 2.8. ALFA<sub>5</sub>-Cy5-BG



DBCO-NHS ester (0.32 mg, 0.74  $\mu\text{mol}$ , 1 equiv.) in DMSO (10  $\mu\text{L}$ ) (from the fresh stock solution of 1.00 mg in 30  $\mu\text{L}$  of DMSO) was added to compound **5** (1.00 mg, 0.74  $\mu\text{mol}$ , 1 equiv.), DIPEA (0.52  $\mu\text{L}$ , 2.96  $\mu\text{mol}$ , 4 equiv.) in DMSO (30  $\mu\text{L}$ ) and stirred at 20  $^{\circ}\text{C}$  for 30 min. Then, 20  $\mu\text{L}$  of reaction mixture was taken off and added to the N<sub>3</sub>-(PEG<sub>2</sub>-ALFA)<sub>5</sub> (4.67 mg, 0.45  $\mu\text{mol}$ , 1.5 equiv.) in distilled water (50  $\mu\text{L}$ ). The reaction mixture was stirred further for 6 h before 70  $\mu\text{L}$  of acetonitrile, 1  $\mu\text{L}$  of acetic acid were added and subjected to RP-HPLC purification. The product containing fractions were pooled and the desired product was obtained after lyophilization (1.68 mg, 140 nmol, 20%) as a blue powder.

**HRMS** (ESI): calc. for C<sub>529</sub>H<sub>871</sub>N<sub>158</sub>O<sub>158</sub> [M]<sup>+</sup>: 11972.7, found: 11970.2.

**LCMS traces:**



### 3. Protein expression and purification

SNAP<sub>f</sub> and HTP were expressed and purified as described previously.<sup>[1]</sup> Briefly, proteins were expressed in *E. coli* strain BL21 (DE3). LB media contained ampicillin (100 µg/mL) for protein expression. A culture was grown at 37 °C until an OD<sub>600</sub> of 0.6 was reached at which point cells were induced with IPTG (1 mM). Protein constructs were expressed overnight at 16 °C. Cells were harvested by centrifugation and sonicated to produce cell lysates. The lysate was cleared by centrifugation and purified by Ni-NTA resin (ThermoFisher) according to the manufacturer's protocols. Purified protein samples were aliquoted in PBS, flash frozen and stored at -80 °C.

SNAP<sub>f</sub> sequence:

MAS<sup>W</sup><sup>S</sup><sup>H</sup><sup>P</sup><sup>Q</sup><sup>F</sup><sup>E</sup><sup>K</sup>G<sup>A</sup><sup>D</sup><sup>D</sup><sup>D</sup><sup>D</sup><sup>K</sup>V<sup>P</sup><sup>H</sup><sup>M</sup><sup>D</sup><sup>K</sup><sup>D</sup><sup>C</sup><sup>E</sup><sup>M</sup><sup>K</sup><sup>R</sup><sup>T</sup><sup>T</sup><sup>L</sup><sup>D</sup><sup>S</sup><sup>P</sup><sup>L</sup><sup>G</sup><sup>K</sup><sup>L</sup><sup>E</sup><sup>L</sup><sup>S</sup><sup>G</sup><sup>C</sup><sup>E</sup><sup>Q</sup><sup>Q</sup><sup>L</sup><sup>H</sup><sup>E</sup><sup>I</sup><sup>I</sup><sup>F</sup><sup>L</sup><sup>G</sup><sup>K</sup><sup>G</sup><sup>T</sup>  
SAADAVEVPAPAAVLGGPEPLMQATAWLNAYFHQPEAIEEFPVPALHHPVFQQESFTRQ  
VLWKKLLKVVKFGEVISYSHLAALAGNPAATAAVKTALSGNPVPIILIPCHRVVQGDLDVG  
GYEGGLAVKEWLLAHEGHRLGKPGLGAPGFSSISA<sup>H</sup><sup>H</sup><sup>H</sup><sup>H</sup><sup>H</sup><sup>H</sup><sup>H</sup><sup>H</sup><sup>H</sup><sup>H</sup><sup>H</sup>

<sup>W</sup><sup>S</sup><sup>H</sup><sup>P</sup><sup>Q</sup><sup>F</sup><sup>E</sup><sup>K</sup>, <sup>A</sup><sup>D</sup><sup>D</sup><sup>D</sup><sup>D</sup><sup>K</sup>, SNAP<sub>f</sub>, <sup>H</sup><sup>H</sup><sup>H</sup><sup>H</sup><sup>H</sup><sup>H</sup><sup>H</sup><sup>H</sup><sup>H</sup><sup>H</sup><sup>H</sup>

HTP sequence:

MAS<sup>W</sup><sup>S</sup><sup>H</sup><sup>P</sup><sup>Q</sup><sup>F</sup><sup>E</sup><sup>K</sup>G<sup>A</sup><sup>D</sup><sup>D</sup><sup>D</sup><sup>D</sup><sup>K</sup>V<sup>P</sup><sup>H</sup><sup>G</sup><sup>S</sup><sup>E</sup><sup>I</sup><sup>G</sup><sup>T</sup><sup>G</sup><sup>F</sup><sup>P</sup><sup>F</sup><sup>D</sup><sup>P</sup><sup>H</sup><sup>Y</sup><sup>V</sup><sup>E</sup><sup>V</sup><sup>L</sup><sup>G</sup><sup>E</sup><sup>R</sup><sup>M</sup><sup>H</sup><sup>Y</sup><sup>V</sup><sup>D</sup><sup>V</sup><sup>G</sup><sup>P</sup><sup>R</sup><sup>D</sup><sup>G</sup><sup>T</sup><sup>P</sup><sup>V</sup><sup>L</sup><sup>F</sup><sup>L</sup>  
HGNPTSSYVWRNIIPHVAPTHRCIAPDLIGMGKSDKPDLYFFDDHVRFMDFIEALGL  
EEVVLVIHDWGSALGFHWAKRNPERVKGIAFMFIRPIPTWDEWPEFARETFQAFRTTD  
VGRKLIIDQNVFIEGTLPMGVVRPLTEVEMDHYREPFLNPVDREPLWRFPNELPIAGEP  
ANIVALVEEYMDWLHQSPVPKLLFWGTGVLIPPAEAARLAKSLPNCKAVDIGPGLNLL  
QEDNPDIGSEIARWLSTLEISGAPGFSSISA<sup>H</sup><sup>H</sup><sup>H</sup><sup>H</sup><sup>H</sup><sup>H</sup><sup>H</sup><sup>H</sup><sup>H</sup><sup>H</sup><sup>H</sup>


<sup>W</sup><sup>S</sup><sup>H</sup><sup>P</sup><sup>Q</sup><sup>F</sup><sup>E</sup><sup>K</sup>, <sup>A</sup><sup>D</sup><sup>D</sup><sup>D</sup><sup>D</sup><sup>K</sup>, HTP, <sup>H</sup><sup>H</sup><sup>H</sup><sup>H</sup><sup>H</sup><sup>H</sup><sup>H</sup><sup>H</sup><sup>H</sup><sup>H</sup><sup>H</sup>

#### 4. Protein mass spectroscopy

Labelling substrates were dissolved in DMSO to a concentration of 1 mM and diluted in PBS (pH = 7.4) to obtain a concentration of 20  $\mu$ M. Protein were diluted in PBS to a concentration of 10  $\mu$ M. 20  $\mu$ L of each protein and labelling agent were combined in a mass spec vial and allowed to incubate at room temperature for 1 h, before full protein mass was acquired. For non-labelling control, 20  $\mu$ L of PBS was mixed with 20  $\mu$ L of each protein.

Conditions	Calculated	Found
HTP	37989	37989
ALFA <sub>5</sub> -Cy5-HTL	11926	11924
HTP: Cy5-ALFA <sub>5</sub>	49878	49876
SNAP	23853	23852
ALFA <sub>5</sub> -Cy5-BG	11972	11970
SNAP: Cy5-ALFA <sub>5</sub>	35674	35671

## 5. Supplementary Figure



**Supplemental Figure 1.** Confocal images of SNAP-HTP-mGluR2 transfected HEK293 cells on a Leica SP8 TCS STED FALCON.

## 6. Cell culture and imaging

HEK293T cells (70,000) were seeded on 8-well, PLL coated ibidi dishes in full media (DMEM high glucose, stable glutamax, 10% FCS) and transfected the next day with 50 ng of plasmid SNAP-HTP-mGluR2,<sup>[2]</sup> using JETPrime (VWR) according to the manufacturer's instructions. Medium was exchanged after 4 hours post transfection, and cells were incubated overnight at 37 °C. The next day, cells were stained with 1 μM SBG-OG<sup>[3]</sup> and 500 nM ALFA<sub>5</sub>-Cy5-HTL and 1 μM Hoechst33342, or 1 μM AF488-HTL and ALFA<sub>5</sub>-Cy5-BG and 1 μM Hoechst33342 for 30 min at 37 °C, before washing once with media. Cells were fixed using 2% PFA (Alfa Aesar) for 20 min at room temperature and washed 3 times with PBS afterwards. The incubation with the anti-ALFA-Nb643 (Nano-Tag, Fluo-Tag-X2 anti-Alfa, ATTO643) was performed over night at 0 °C. Cells were washed 3 times with PBS and fixed again with 2% PFA for 20 minutes. Cells were washed again 3 times with PBS and imaged in PBS on a Nikon CSU-X1 using a 40x objective (air), equipped with a EMCCD camera (Andor AU-888), fast triggered acquisition and a piezo Z-drive for fast imaging. Incubator (OKOLAB) was set to 37 °C with 5% CO<sub>2</sub>. Lasers used: 405 nm 488 nm, 561 nm, and 638 nm. STED was performed on a Leica SP8 TCS STED FALCON (Leica Microsystems) equipped with a pulsed white-light excitation laser (80 MHz repetition rate, NKT Photonics), a 100 objective (HC PL APO CS2 100/ 1.40 NA oil), operated by LAS X.  $\lambda_{\text{Ex}} = 640 \text{ nm}$   $\lambda_{\text{Em}} = 655\text{--}748 \text{ nm}$ . The confocal images were collected using a time gated Hybrid detector (0.5–6 ns).

## **7. Non-denaturing SDS-PAGE**

Peptides ALFA5-Cy5-HTL or ALFA5-Cy5-BG were diluted to 5 nM in PBS and incubated with anti-ALFA-Nb643 (0, 0.1, 1, 10 or 100 nM) for 30 min at room temperature. The samples were diluted with a non-reducing loading buffer (Carl Roth) and loaded onto a gradient gel (4–20% Mini-PROTEAN® TGX™ Precast Protein Gel) without boiling. The anti-Alfa Nb643 was also loaded in a concentration of 100 nM. A low range marker (Thermo Fisher) was applied to estimate the size of the peptides. The gel was imaged at a fluorescence scanner using 635 nm and 400V laserpower.

## **8. Image Calculation and Statistics**


For image representation FIJI was used with the integrated *Calculator Plus* to obtain ratiometric images. Statistics were performed in Prism 10.

## 9. Excitation and Emission profiles

ALFA<sub>5</sub>-Cy5-HTL or ALFA<sub>5</sub>-Cy5-BG were dissolved in DMSO to a concentration of 1 mM and diluted in PBS (pH = 7.4) to obtain a concentration of 200 nM. 200  $\mu$ L solution was transferred into Greiner black flat bottom 96 well plate and excitation and emission profiles were recorded on a TECAN INFINITE M PLEX plate reader ( $\lambda_{\text{Ex}} = 605 \pm 10$  nm;  $\lambda_{\text{Em}} = 640\text{--}800 \pm 20$  nm; 10 flashes; 20  $\mu$ s integration time). Data normalization, integration and plotting was performed in GraphPad Prism 8.

ALFA<sub>5</sub>-Cy5-HTL:  $\lambda_{\text{max Ex}} = 651$  nm;  $\lambda_{\text{max Em}} = 674$  nm

ALFA<sub>5</sub>-Cy5-BG:  $\lambda_{\text{max Ex}} = 650$  nm;  $\lambda_{\text{max Em}} = 668$  nm



## 10. References

- [1] R. Birke, J. Ast, D. A. Roosen, J. Lee, K. Roßmann, C. Huhn, B. Mathes, M. Lisurek, D. Bushiri, H. Sun, B. Jones, M. Lehmann, J. Levitz, V. Haucke, D. J. Hodson, J. Broichhagen, *Org. Biomol. Chem.* **2022**, *20*, 5967–5980.
- [2] K. Roßmann, R. Birke, J. Levitz, B. Jones, J. Broichhagen, *RSC Chem. Biol.* **2025**, 10.1039.D4CB00209A.
- [3] P. Poc, V. A. Gutzeit, J. Ast, J. Lee, B. J. Jones, E. D'Este, B. Mathes, M. Lehmann, D. J. Hodson, J. Levitz, J. Broichhagen, *Chem. Sci.* **2020**, *11*, 7871–7883.